Ocular Therapeutix reported a second quarter net loss of $24.5 million, or $0.57 per share, compared with a net loss of $13.8 million, or $0.37 per share, for the same period in 2018, according to a press release.
Revenues were $600,000, the same as in 2018.
Research and development expenses were $9.4 million compared with $8.7 million in the comparable period in 2018. General and administrative expenses were $5.1 million compared with $4.4 million in 2018.
Selling and marketing expenses were $7.2 million compared with $900,000 in the second quarter (Read more...)
Uncategorized